Dasatinib (BMS-354825) targeting SRC kinase suppresses HER2-overexpressing breast cancer progression
Copy code to add this image to your page
In HER2-overexpressing breast carcinomas, hyperactivation of human epidermal growth factor receptor 2 triggers dense intracellular signaling networks through heterodimerization with EGFR or HER3. Standard targeted regimens using the monoclonal antibody trastuzumab frequently suffer from clinical relapse driven by bypass signaling mechanisms. Non-receptor tyrosine kinase SRC serves as a critical signaling hub immediately downstream of HER2. Reciprocal transactivation between HER2 and SRC amplifies survival cascades, conferring acquired resistance to monoclonal antibody monotherapy. Dasatinib (BMS-354825) is an ATP-competitive, small-molecule inhibitor targeting SRC family kinases with low nanomolar potency. By binding the active conformation of the SRC kinase domain, BMS-354825 prevents Y416 autophosphorylation, effectively decoupling HER2 receptor signaling from efferent survival cascades. However, systemic administration of free tyrosine kinase inhibitors often encounters biopharmaceutic limitations, including rapid clearance, non-specific distribution, and narrow therapeutic windows.
To resolve these pharmacokinetic constraints, engineered nanocarriers offer a targeted approach for intracellular drug delivery. Recent experimental work established trastuzumab-targeted biodegradable polylactide nanoparticles functionalized with polyethylenimine and loaded with dasatinib, designated as TAB-DAS-(PEI)NPs. The polylactide polymer matrix provides a biocompatible matrix for hydrophobic drug entrapment, while polyethylenimine coating supplies surface amine groups for covalent conjugation with trastuzumab (TAB). Physicochemical characterization of TAB-DAS-(PEI)NPs demonstrated high drug encapsulation efficiency alongside uniform, sub-200 nanometer particle size distribution. In vitro dissolution profiles in physiological buffer systems confirmed sustained release kinetics without an initial burst effect, ensuring stable delivery within circulation prior to receptor engagement.
Targeting efficacy was evaluated in human breast adenocarcinoma cell lines exhibiting distinct HER2 expression and resistance phenotypes. Assays utilized parental BT474 cells alongside a trastuzumab-resistant subclone, BT474-RH. In both models, surface functionalization with trastuzumab facilitated targeted binding to extracellular HER2 epitopes, triggering clathrin-mediated endocytosis of the loaded nanocarriers. Quantitative intracellular uptake studies demonstrated significantly higher accumulation of dasatinib when delivered via TAB-DAS-(PEI)NPs compared to non-targeted nanoparticles or free drug suspensions. This elevated intracellular concentration translated directly into augmented pharmacological activity under tested in vitro assay conditions.
Biochemical analysis of treated cell lysates revealed potent attenuation of SRC phosphorylation at Tyr416 following treatment with TAB-DAS-(PEI)NPs. Downstream nodes within the PI3K-AKT and Ras-Raf-MEK-ERK signaling cascades exhibited corresponding decreases in active phosphorylation states. Loss of AKT-mediated inhibitory phosphorylation on p27Kip1 enabled the cyclin-dependent kinase inhibitor to accumulate within the nucleus. Flow cytometric cell-cycle profiling indicated a pronounced shift toward G0/G1 phase arrest in both BT474 and BT474-RH lines. This arrest was accompanied by downregulation of cyclin D1 and CDK4 proteins, effectively halting cell-cycle progression.
The therapeutic benefit of targeted nanoparticle delivery extended to the induction of programed cell death. Apoptotic response markers, including mitochondrial membrane depolarization, cleavage of poly(ADP-ribose) polymerase (PARP), and activation of caspase-3, were significantly elevated in cells exposed to TAB-DAS-(PEI)NPs relative to free dasatinib or trastuzumab alone. Furthermore, three-dimensional tumor spheroid assays were conducted to model solid tumor architecture and interstitial transport barriers. TAB-DAS-(PEI)NPs demonstrated superior spheroid penetration, resulting in profound volume reduction and structural disintegration of 3D BT474-RH microtumors over prolonged incubation periods.
These empirical findings demonstrate that nanocarrier-mediated delivery of BMS-354825 overcomes acquired resistance mechanisms driven by SRC activation in HER2+ breast cancer models. By combining active antibody targeting with sustained intracellular kinase inhibition, TAB-DAS-(PEI)NPs provide a strategy to restore therapeutic sensitivity in treatment-refractory cell populations.
Pharmacological Evaluation and Cytotoxic Dynamics
Copy code to add this image to your page
Dasatinib (BMS-354825) acts as a potent small-molecule inhibitor of SRC family kinases. By occupying the ATP-binding pocket of SRC kinase, it halts autophosphorylation at Tyr416 and blocks downstream signal transmission through FAK, AKT, and ERK cascades. In HER2-overexpressing breast cancer cells, targeted delivery via trastuzumab-conjugated nanoparticles (TAB-DAS-(PEI)NPs) enhances intracellular drug accumulation. Blockade of SRC signaling suppresses cyclin D1 expression while elevating p27Kip1, enforcing G0/G1 cell-cycle arrest. Concurrently, loss of survival signaling triggers mitochondrial membrane depolarization and cleavage of caspase-3, driving targeted apoptotic cell death.
Targeted Nanoparticles Restrict Proliferation in Trastuzumab-Resistant Cells
Quantitative cytotoxicity assays demonstrated that TAB-DAS-(PEI)NPs reduced cell viability in BT474-RH models more effectively than equivalent doses of unencapsulated drug. Free BMS-354825 displayed moderate potency. Nanoparticle delivery restored sensitivity. Active receptor binding mediated rapid endocytosis. Intracellular concentration of the inhibitor increased fourfold relative to passive diffusion control groups. Under these in vitro conditions, cell viability dropped below twenty percent within forty-eight hours.
Blockade of SRC Signaling Arrests Cell-Cycle Progression
Flow cytometry confirmed that treatment with TAB-DAS-(PEI)NPs induced marked G0/G1 phase arrest in HER2-overexpressing cell lines. Downstream phosphorylation of AKT and ERK ceased within two hours of exposure. Cyclin D1 expression decreased rapidly. Nuclear p27Kip1 levels accumulated proportionately. In 3D spheroid models, structural integrity degraded completely over seven days of treatment. These observations indicate that targeted inhibition with BMS-354825 effectively disrupts survival pathways required for sustained tumor architecture.